3B BlackBio Dx Ltd (3BBLACKBIO.BO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 31 | 11 | 8 | 9 | 11 | 15 | 17 | 15 |
| Operating profit | $m | 6 | 5 | ||||||
| Net profit | $m | 16 | 4 | 3 | 4 | 6 | 6 | 6 | 5 |
| EPS reported | $ | 0.75 | 0.71 | ||||||
| Operating cashflow per share | $ | 0.67 | 0.00 | ||||||
| Capex per share | $ | 0.33 | 0.00 | ||||||
| FCF per share | $ | 0.34 | 0.00 | ||||||
| Free cash flow | $m | 3 | - | ||||||
| Net debt | $m | -10 | -10 | ||||||
| Book value equity | $m | 35 | 35 | ||||||
| Book value per share | $ | 4.17 | 4.07 | ||||||
| Number of shares | m | 8.38 | 8.58 | ||||||
| DPS (TTM paid) | $ | 0.05 | 0.05 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 16.05 | 21.59 | ||||||
| P/B LTM | x | 4.81 | 4.81 | ||||||
| P/S LTM | x | 11.00 | 10.02 | ||||||
| P/FCF LTM | x | 58.40 | 0.00 | ||||||
| EV/EBITDA LTM | x | 27.26 | 28.29 | ||||||
| EV/Sales LTM | x | 5.92 | 7.32 | ||||||
| Earnings Yield LTM | % | +6.23% | +4.63% | ||||||
| FCF Yield | % | +1.71% | 0.00% | ||||||
| Quality | |||||||||
| ROE | % | +18.06% | +18.33% | ||||||
| ROIC | % | +11.78% | +10.77% | ||||||
| Operating margin | % | +36.39% | +31.15% | ||||||
| Gross margin | % | +54.24% | +51.31% | ||||||
| FCF/Sales | % | +18.83% | 0.00% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +15.38% | +9.23% | ||||||
| Sales Growth YoY | % | +35.35% | +48.51% | ||||||
| Net Income Growth YoY | % | +13.02% | +9.47% | ||||||
| FCF Growth | % | -42.08% | - | ||||||
| Operating Profit Growth | % | -3.65% | -9.52% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.36% | +0.27% | ||||||
| Dividend Growth | % | +26.88% | +26.88% | ||||||
| Payout Ratio | % | +5.86% | +5.84% | ||||||
| FCF/Debt | x | 8.60 | - | ||||||
| Net Debt/EBITDA | x | -1.72 | -1.78 | ||||||
| EBIT/Net interest | x | 217.84 | 146.40 | ||||||
| Net debt/market cap | % | +0.33% | +0.25% | ||||||
| Net debt/Equity | x | -0.30 | -0.30 | ||||||
| Gross debt/equity | x | 0.01 | 0.01 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in 1972 and headquartered in Bhopal, India, 3B Blackbio Dx Limited specializes in the conception, production, and market distribution of sophisticated molecular diagnostic technologies. The company's core focus is on delivering solutions for pressing health concerns such as infectious diseases, oncology, human genetics, and the challenge of antimicrobial resistance, primarily serving the Indian market. Their comprehensive product portfolio includes qPCR-based assays, swift lateral flow rapid tests, and cutting-edge Next Generation Sequencing (NGS) molecular diagnostic kits. These offerings are designed to enable precise and dependable analysis of patient samples by diagnostic laboratories, marketed under reputable brands like TRUPCR, TRUNGS, and TRURAPID. Beyond diagnostics, 3B Blackbio Dx Limited also supplies agrochemical products and provides essential technical support and training services.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
3B BlackBio Dx Ltd (3BBLACKBIO.BO)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Established in 1972 and headquartered in Bhopal, India, 3B Blackbio Dx Limited specializes in the conception, production, and market distribution of sophisticated molecular diagnostic technologies. The company's core focus is on delivering solutions for pressing health concerns such as infectious diseases, oncology, human genetics, and the challenge of antimicrobial resistance, primarily serving the Indian market. Their comprehensive product portfolio includes qPCR-based assays, swift lateral flow rapid tests, and cutting-edge Next Generation Sequencing (NGS) molecular diagnostic kits. These offerings are designed to enable precise and dependable analysis of patient samples by diagnostic laboratories, marketed under reputable brands like TRUPCR, TRUNGS, and TRURAPID. Beyond diagnostics, 3B Blackbio Dx Limited also supplies agrochemical products and provides essential technical support and training services.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free